Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unesbulin + Dacarbazine in Advanced Leiomyosarcoma
NCT03761095Phase 1Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Mar 2019
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of unesbulin in leiomyosarcoma (LMS), sponsored by PTC Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 6 weeks, Recommended Phase 2 Dose at 6 weeks and 1 more. Started Mar 2019; status: completed.
02
Drugs
unesbulin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT03761095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761095.